全文获取类型
收费全文 | 6225篇 |
免费 | 291篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 134篇 |
儿科学 | 160篇 |
妇产科学 | 143篇 |
基础医学 | 655篇 |
口腔科学 | 482篇 |
临床医学 | 330篇 |
内科学 | 1723篇 |
皮肤病学 | 114篇 |
神经病学 | 460篇 |
特种医学 | 118篇 |
外科学 | 844篇 |
综合类 | 18篇 |
一般理论 | 1篇 |
预防医学 | 534篇 |
眼科学 | 182篇 |
药学 | 296篇 |
中国医学 | 15篇 |
肿瘤学 | 339篇 |
出版年
2024年 | 6篇 |
2023年 | 54篇 |
2022年 | 116篇 |
2021年 | 242篇 |
2020年 | 121篇 |
2019年 | 145篇 |
2018年 | 207篇 |
2017年 | 153篇 |
2016年 | 168篇 |
2015年 | 199篇 |
2014年 | 293篇 |
2013年 | 319篇 |
2012年 | 541篇 |
2011年 | 530篇 |
2010年 | 262篇 |
2009年 | 225篇 |
2008年 | 394篇 |
2007年 | 428篇 |
2006年 | 375篇 |
2005年 | 326篇 |
2004年 | 305篇 |
2003年 | 264篇 |
2002年 | 228篇 |
2001年 | 47篇 |
2000年 | 45篇 |
1999年 | 48篇 |
1998年 | 29篇 |
1997年 | 27篇 |
1996年 | 22篇 |
1995年 | 22篇 |
1994年 | 28篇 |
1993年 | 15篇 |
1992年 | 33篇 |
1991年 | 35篇 |
1990年 | 38篇 |
1989年 | 42篇 |
1988年 | 22篇 |
1987年 | 19篇 |
1986年 | 21篇 |
1985年 | 17篇 |
1984年 | 16篇 |
1983年 | 8篇 |
1982年 | 13篇 |
1981年 | 13篇 |
1980年 | 11篇 |
1979年 | 6篇 |
1977年 | 11篇 |
1976年 | 8篇 |
1975年 | 6篇 |
1971年 | 5篇 |
排序方式: 共有6548条查询结果,搜索用时 31 毫秒
81.
Overweight,obese, underweight,and frequency of sugar consumption as risk indicators for early childhood caries in Brazilian preschool children 下载免费PDF全文
Cecilia Claudia Costa Ribeiro Mariana Carvalho Batista da Silva Ana Margarida Melo Nunes Erika Bárbara de Abreu Fonseca Thomaz Cadidja Dayane Sousa Carmo Marizélia Rodrigues Costa Ribeiro Antônio Augusto Moura da Silva 《International journal of paediatric dentistry / the British Paedodontic Society [and] the International Association of Dentistry for Children》2017,27(6):532-539
82.
83.
84.
85.
86.
Marco Aurélio Petroni Montezuma Felipe Paiva Fonseca Bernar Monteiro Benites Ciro Dantas Soares Gleyson Kleber do Amaral-Silva Oslei Paes de Almeida Fernando Augusto Soares Rosana Lima Pagano Eduardo Rodrigues Fregnani 《Pathology, research and practice》2018,214(6):907-913
Ameloblastoma is a locally aggressive neoplasm with a poorly understood pathogenesis. Therefore, the aim of this study is to investigate whether COX-2 expression is associated with ameloblastoma microvascular density (MVD) and with tumor aggressiveness. Sixty-three cases of primary ameloblastomas arranged in tissue microarray were submitted to immunohistochemistry against cyclooxigenase-2 (COX-2) and CD34. Clinicopathological parameters regarding sex, age, tumour size, tumour duration, tumour location, treatment, recurrences, radiographic features, vestibular/lingual and basal cortical disruption and follow-up data were obtained from patients’ medical records and correlated with the proteins expression. The results on BRAF-V600E expression were obtained from our previous study and correlated with COX-2 and CD34 expressions. Log-rank univariate analysis and multivariate Cox regression model were done to investigate the prognostic potential of the molecular markers. Twenty-eight cases (44.4%) exhibited cytoplasmic positivity for COX-2, predominantly in the columnar peripheral cells, with a mean MVD of 2.2 vessels/mm2. COX-2 was significantly associated with recurrences (p?<?0.001) and BRAF-V600E expression (p?<?0.001), whereas lower MVD was associated with the use of conservative therapy (p?=?0.004). Using univariate and multivariate analyses, COX-2 was significantly associated with a lower 5-year disease-free survival (DFS) rate (p?<?0.001 and p?=?0.012, respectively), but not with a higher MVD (p?=?0.68). In conclusion, COX-2 expression in ameloblastomas is not associated with MVD, but it is significantly associated with recurrences and with a lower DFS. 相似文献
87.
Luca Arcaini Michele Merli Francesco Passamonti Raffaele Bruno Ercole Brusamolino Paolo Sacchi Sara Rattotti Ester Orlandi Elisa Rumi Virginia Ferretti Silvia Rizzi Erika Meli Cristiana Pascutto Marco Paulli Mario Lazzarino 《American journal of hematology》2010,85(1):46-50
We studied 160 Hepatitis C virus (HCV)‐positive patients with NHL (59 indolent NHL, 101 aggressive). Median age was 67 years. HCV‐RNA was present in 146. HBsAg was positive in seven patients. At diagnosis, ALT value was above UNL in 67 patients. One hundred and twenty patients received an anthracycline‐based therapy, alkylators, 28 received chemotherapy plus rituximab. Cytotoxic drugs dose was reduced in 63 patients. Among 93 patients with normal ALT at presentation, 16 patients developed WHO grade II–III liver toxicity. Among 67 patients with abnormal ALT, eight patients had a 3.5 times elevation during treatment. Among 28 patients treated with rituximab and chemotherapy, five patients (18%) developed liver toxicity. Thirty four patients (21%) did not complete treatment (eight for liver toxicity). Median progression‐free survival (PFS) for patients who experienced liver toxicity is significantly shorter than median PFS of patients without toxicity (respectively, 2 years and 3.7 years, P = 0.03). After a median F‐UP of 2 years, 32 patients died (three for hepatic failure). A significant proportion of patients with HCV+ NHL develop liver toxicity often leading to interruption of treatment. This could be a limit to the application of immunochemotherapy programs. HCV+ lymphomas represent a distinct clinical subset of NHL that deserves specific clinical approach to limit liver toxicity and ameliorate survival. Am. J. Hematol., 2010. © 2009 Wiley‐Liss, Inc. 相似文献
88.
Roy P Bonello L de Labriolle A Okabe T Pinto Slottow TL Steinberg DH Torguson R Smith K Xue Z Satler LF Kent KM Suddath WO Pichard AD Waksman R 《The American journal of cardiology》2008,102(3):292-297
Multiple studies comparing sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with coronary artery disease have been performed. Despite these comparisons, it remains uncertain whether a differential in long-term efficacy and safety exists. Unselected patients treated exclusively with 1 drug-eluting stent type were enrolled in the Registry Experience at the Washington Hospital Center with Drug-Eluting Stents. There were 2,099 patients (3,766 lesions) treated with SES and 1,079 patients (1,850 lesions) treated with PES. Patients were followed at 30 days, 1 year, and 2 years for the clinical endpoints of death, myocardial infarction, target vessel revascularization, and definite and definite/probable stent thrombosis. Patients in the SES group had more dyslipidemia, history of congestive heart failure, and ostial lesions; patients treated with PES had more previous coronary artery bypass surgery, unstable angina, and type C lesions. At 2 years, unadjusted major adverse cardiac events (MACE) (22.6% vs 21.1%, p = 0.3) and target vessel revascularization (13.3% vs 11.2%, p = 0.1) were comparable. The incidence of definite stent thrombosis was higher in the SES group (1.8% vs 0.9%, p = 0.05) driven by early events. Similar results were seen after adjustment for baseline differences: MACE (hazard ratio 1.1, 95% confidence interval [CI] 0.9 to 1.3, p = 0.5), definite stent thrombosis (hazard ratio 2.3, 95% CI 1.0 to 5.2, p = 0.05), and target vessel revascularization (hazard ratio 1.1, 95% CI 0.9 to 1.4, p = 0.4). The incidence and rate of late stent thrombosis (>30 days) were similar (0.7% vs 0.5%, p = 0.4 and 0.24%/year, both groups, respectively). In conclusion, no major differential in long-term safety or efficacy was detected between SES and PES; both stent types were efficacious in reducing revascularization but were limited by a small continual increase in late stent thrombosis. 相似文献
89.
90.